Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783712 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BTP53ELANEFAAH | |
| SCHEMBL13058472 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BTP53 | |
| SCHEMBL13058666 | 0.80 | MTNR1A (0.49) | MTNR1AMTNR1BTP53MAPTMAOA | |
| SCHEMBL20964603 | 0.80 | PSMB8 (0.51) | MTNR1AMTNR1BMAPT | |
| SCHEMBL13058661 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BTP53ELANEMAPT | |
| SCHEMBL25478515 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BTP53ELANEMAPT | |
| SCHEMBL13058672 | 0.77 | MTNR1A (0.60) | MTNR1AMTNR1BTP53 | |
| SCHEMBL13058667 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BELANEMAPTMAOA | |
| SCHEMBL5542790 | 0.76 | ELANE (0.56) | MTNR1AMTNR1BELANEFAAHMAPT | |
| SCHEMBL25488150 | 0.76 | MTNR1A (0.43) | MTNR1AMTNR1BELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| EP-3471729-B1 | ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION | UNIV RUTGERS (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | NQO1, COQ8A, NDUFAB1 | MTNR1A 298/4885MTNR1B 415/4885TP53 976/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | MTNR1A 4801/4885MTNR1B 4678/4885TP53 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.